home / stock / gnmsf / gnmsf message board
Subject | By | Source | When |
---|---|---|---|
Products in development | XenaLives | investorshub | 10/27/2019 2:32:31 PM |
Product pipeline | XenaLives | investorshub | 10/27/2019 2:32:00 PM |
About Genmab A/S | XenaLives | investorshub | 10/27/2019 2:25:49 PM |
$GMXAY largest holding in Blackrock fund: | XenaLives | investorshub | 10/27/2019 2:23:21 PM |
Genmab Announces Phase II Study of Daratumumab in | PennyStock Alert | investorshub | 09/16/2019 12:43:50 PM |
GMXAY Forward Split 5 for 1 effective May | TenKay | investorshub | 04/17/2018 2:17:06 AM |
Here are Two Biotech Stocks to Watch in | trendmkr | investorshub | 12/31/2015 11:04:54 PM |
$GMXAY DD Notes ~ http://www.ddnotesmaker.com/$GMXAY | stocktrademan | investorshub | 12/04/2014 7:43:31 PM |
Genmab has taken a beating along with a | akademikeren | investorshub | 04/15/2014 9:55:50 AM |
Stock Tracker: Latest Genmab A/S Dkk (GNMSF) Headlines Genmab Announces Phase III Study of Daratumum | Stock_Tracker | investorshangout | 03/10/2014 4:46:26 AM |
chartguy89: GNMSF 46.72 Stock Charts $GNMSF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 6:03:52 PM |
chartguy89: GNMSF Stock Charts Last: -0.30 Wednesday, February 26, 2014 at 1:11:32 PM $GNMSF | chartguy89 | investorshangout | 02/26/2014 6:11:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Dkk Company Name:
GNMSF Stock Symbol:
OTCMKTS Market:
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark;...
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for...